03/22/23 3:45 PMNYSE : MRK Amplifying the Power of Women in ChemistryMerck & Co., Inc. For Dr. Rebecca Ruck, having more women in science is personal. She remembers times early in her career when she was the only woman in the room. That's why she co-founded the Merck Research Award, given annually by the Women ChemistsRHEA-AIvery positive
03/16/23 4:05 PMNYSE : MRK clinical trialMerck Provides Update from Open-Label Arm of Phase 2 KeyVibe-002 Trial Evaluating MK-7684A, a Coformulation of Vibostolimab and Pembrolizumab, in Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)Merck, known as MSD outside of the United States and Canada, today provided an update on the open-label arm of the non-registrational Phase 2 KeyVibe-002 trial. Merck is notifying study investigators that patients in this arm of the study should be switched to a standard of care, unless their physician considers the patient is benefitting from MK-7684A alone.RHEA-AIneutral
03/10/23 6:45 AMNYSE : MRK KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Advanced Malignant Pleural MesotheliomaMerck, known as MSD outside of the United States and Canada, and the Canadian Cancer Trials Group today announced that the Phase 2/ 3 CCTG IND.227/KEYNOTE-483 trial evaluating KEYTRUDA, Merck’ s anti-PD-1 therapy, in combination with chemotherapy met its primary endpoint of overall survival for the first-line treatment of...RHEA-AIneutral
03/08/23 6:45 AMNYSE : MRK conferencesMerck to Present at the Barclays 2023 Global Healthcare ConferenceMerck, known as MSD outside of the United States and Canada, announced today that Jannie Oosthuizen, president, Human Health U.S., is scheduled to participate in a fireside chat at the Barclays 2023 Global Healthcare Conference on Wednesday, March 15, 2023, at 2:35 p.m. ET. Forward-Looking Statement of Merck& Co., Inc., Rahway, N.J., USA. This news release of Merck& Co.,...RHEA-AIneutral
03/07/23 11:15 AMNYSE : MRK Black Scientists, Innovators and Employees are Key to Merck’s History of Invention and ProgressMerck & Co., Inc. Susan R. Jenkins in the lab, ca. 1969. A diverse workforce is not only fundamental to the company's future success, but it's also a part of its rich history. Taking a look back in time, the company highlights the contributions ofRHEA-AIvery positive
03/06/23 12:01 PMNYSE : MRK Merck’s Investigational Activin Signaling Inhibitor Sotatercept Improved Six-Minute Walk Distance by 40.8 Meters at Week 24 Versus Placebo in Adults with Pulmonary Arterial Hypertension on Background TherapyMerck, known as MSD outside of the United States and Canada, today announced full results from the Phase 3 STELLAR trial, which evaluated sotatercept, Merck’ s novel investigational activin signaling inhibitor biologic, in combination with stable background therapy for the treatment of adult patients with pulmonary arterial hypertension.RHEA-AIneutral
03/06/23 12:00 PMNYSE : MRK clinical trialMerck’s MK-0616, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Patients with Hypercholesterolemia in Phase 2b StudyMerck, known as MSD outside of the United States and Canada, today announced results from the Phase 2 b clinical trial evaluating MK-0616, an investigational, once-daily oral proprotein convertase subtilisin/kexin type 9 inhibitor in adults with hypercholesterolemia. At week 8, all doses of MK-0616 significantly reduced LDL-C compared to placebo and the...RHEA-AIneutral
03/06/23 6:45 AMNYSE : MRK fda approvalUS FDA Approves Intramuscular Administration for Merck’s MMRV Family of Vaccines: M-M-RII (Measles, Mumps, and Rubella Virus Vaccine Live), VARIVAX (Varicella Virus Vaccine Live), and ProQuad (Measles, Mumps, Rubella and Varicella Virus Vaccine Live)Merck, known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration has approved the addition of the intramuscular route of administration to the United States Product Insert for Merck’ s MMRV family of vaccines: M-M-R ® II, VARIVAX ®, and ProQuad ®. While these vaccines have a long history in the U.S., until now...RHEA-AIpositive
03/02/23 9:00 AMNYSE : MRK Merck and AstraZeneca Provide Update on US Regulatory Review of LYNPARZA® (olaparib) for Use in Combination With Abiraterone and Prednisone or Prednisolone for the Treatment of Metastatic Castration-Resistant Prostate CancerAstraZeneca and Merck, known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration will convene a meeting of the Oncologic Drugs Advisory Committee to discuss the supplemental new drug application for use of LYNPARZA in combination with abiraterone and prednisone or prednisolone for the treatment of...RHEA-AIneutral
03/01/23 6:45 AMNYSE : MRK clinical trialMerck Announces Phase 3 KEYNOTE-671 Trial Met Primary Endpoint of Event-Free Survival (EFS) in Patients With Resectable Stage II, IIIA or IIIB Non-Small Cell Lung CancerMerck, known as MSD outside of the United States and Canada, announced today that the Phase 3 KEYNOTE-671 trial investigating KEYTRUDA, Merck’ s anti-PD-1 therapy, met one of its dual primary endpoints, event-free survival, as a perioperative treatment regimen for patients with resectable stage II, IIIA or IIIB non-small cell lung cancer. The U.S. Food and Drug...RHEA-AIneutral